In patients' ineligible for cisplatin, pembrolizumab and atezolizumab are first‐line alternatives to carboplatin‐based chemotherapy but limited to patients whose tumours have a high PD‐L1 expression level [6]. This evidence concerns the gene CD274 and neoplasm.